GlaxoSmithKline (GSK) and Dentsply, a provider of dental products, have entered into an agreement to create a portfolio of co-branded oral care products to be used in the dental office by patients suffering from tooth sensitivity.
The agreement will allow Dentsply to co-brand its NUPRO products which contain the NovaMin technology, with GSK‘s Sensodyne brand and the co-branding will provide a continuum of care for tooth sensitivity treatment from the dental office to everyday use at home.
Dentsply president and chief operating officer Christopher Clark said Dentsply and GSK have come together to provide a continuous treatment program for patients who suffer from the problem of tooth sensitivity.
"We are combining some of the most well regarded brands and products on the market to provide a complete treatment solution with both in-office and at-home care regimens for patients suffering from this type of tooth pain. We are pleased to be partnering with GSK and Sensodyne, a global leader in sensitivity treatment," Clark said.
The agreement also provides for the use of both companies’ technical, clinical and marketing resources to offer a comprehensive range of tooth sensitivity treatment options for the dental professional and the patient.
Dentsply plans to release two, co-branded dental products NUPRO Sensodyne Professional prophy paste and Sensodyne NUPRO Professional toothpaste containing the NovaMin technology.